keyword
https://read.qxmd.com/read/38662364/postoperative-hypofractionated-intensity-modulated-radiotherapy-with-concurrent-chemotherapy-in-cervical-cancer-the-pohim-ccrt-nonrandomized-controlled-trial
#1
JOURNAL ARTICLE
Won Kyung Cho, Won Park, Sang-Won Kim, Kang Kyu Lee, Ki Jung Ahn, Jin Hwa Choi
IMPORTANCE: Prospective data assessing the safety of hypofractionated (40 Gy in 16 fractions) radiotherapy (RT) among patients who receive postoperative concurrent chemoradiotherapy for cervical cancer are lacking. OBJECTIVE: To evaluate the acute toxic effects of hypofractionated pelvic intensity-modulated radiotherapy (IMRT) with concurrent chemotherapy among women with cervical cancer who underwent radical hysterectomy. DESIGN, SETTING, AND PARTICIPANTS: The POHIM-CCRT (Postoperative Hypofractionated Intensity-Modulated Radiation Therapy With Concurrent Chemotherapy in Cervical Cancer) study was designed as a multicenter, phase 2 nonrandomized controlled trial that accrued and followed up patients from June 1, 2017, to February 28, 2023...
April 25, 2024: JAMA Oncology
https://read.qxmd.com/read/38660686/the-efficacy-and-safety-of-stereotactic-body-radiotherapy-combined-with-systematic-therapy-for-metastatic-renal-cell-carcinoma-a-systematic-review-and-meta-analysis
#2
JOURNAL ARTICLE
Shiyu Zhang, Xingyu Xiong, Nan Xie, Weitao Zheng, Yongjun Li, Tianhai Lin, Qiang Wei, Ping Tan
There is considerable interest in the potential of stereotactic body radiation therapy (SBRT) combined with systemic therapy such as tyrosine kinase inhibitors (TKIs) or immune checkpoint inhibitors (ICIs). However, its efficacy and safety remain unclear. The purpose of this study was to evaluate the efficacy and safety of conducting SBRT during ICI or TKI treatment in different disease settings for patients with metastatic renal cell carcinoma (mRCC). A total of 16 studies were ultimately included. Under the random effects model, the pooled 1-year local control rate (1-yr LCR) and objective response rate (ORR) were 90% (95% confidence interval [CI]: 80%-95%, I 2  = 67%) and 52% (95% CI: 37%-67%, I 2  = 90%), respectively...
May 2024: MedComm
https://read.qxmd.com/read/38658229/alpha-emitter-peptide-receptor-radionuclide-therapy-in-neuroendocrine-tumors
#3
REVIEW
Sudhir Bhimaniya, Hina Shah, Heather Jacene
Peptide receptor radionuclide therapy (PRRT) has become mainstream therapy of metastatic neuroendocrine tumors not controlled by somatostatin analog therapy. Currently, beta particle-emitting radiopharmaceuticals are the mainstay of PRRT. Alpha particle-emitting radiopharmaceuticals have a theoretic advantage over beta emitters in terms of improved therapeutic efficacy due to higher cancer cell death and lower nontarget tissue radiation-induced adverse events due to shorter path length of alpha particles. We discuss the available evidence for and the role of alpha particle PRRT...
April 23, 2024: PET Clinics
https://read.qxmd.com/read/38655092/molecular-targeted-therapies-for-cutaneous-squamous-cell-carcinoma-recent-developments-and-clinical-implications
#4
REVIEW
Harpreet Singh, Hitesh Chopra, Inderbir Singh, Sourav Mohanto, Mohammed Gulzar Ahmed, Shruti Ghumra, Anmol Seelan, Manisha Survase, Arvind Kumar, Amrita Mishra, Arun Kumar Mishra, Mohammad Amjad Kamal
Cutaneous Squamous Cell Carcinoma (cSCC) is a common and potentially fatal type of skin cancer that poses a significant threat to public health and has a high prevalence rate. Exposure to ultraviolet radiation on the skin surface increases the risk of cSCC, especially in those with genetic syndromes like xerodermapigmentosum and epidermolysis bullosa. Therefore, understanding the molecular pathogenesis of cSCC is critical for developing personalized treatment approaches that are effective in cSCC. This article provides a comprehensive overview of current knowledge of cSCC pathogenesis, emphasizing dysregulated signaling pathways and the significance of molecular profiling...
2024: EXCLI Journal
https://read.qxmd.com/read/38647885/involved-field-radiotherapy-in-older-patients-with-superficial-thoracic-esophageal-squamous-cell-carcinoma-long-term-outcomes-and-recurrence-patterns
#5
JOURNAL ARTICLE
Sawa Kono, Yaichiro Hashimoto, Kenta Ohmatsu, Miki Tsujii, Shigehiko Kuribayashi, Kumiko Karasawa
PURPOSE: An optimal radiotherapy field for superficial esophageal carcinoma is yet to be established. We evaluated the long-term outcomes and recurrence patterns of involved-field radiotherapy (IFRT) in older patients with superficial thoracic esophageal squamous cell carcinoma (ESCC). MATERIALS AND METHODS: Fifty-four patients (49 men and 5 women; mean age, 77 [range: 66-90] years) who underwent IFRT for superficial thoracic ESCC between January 2003 and January 2019 were retrospectively reviewed...
April 22, 2024: Japanese Journal of Radiology
https://read.qxmd.com/read/38647024/gender-difference-in-side-effects-of-immunotherapy-a-possible-clue-to-optimize-cancer-treatment-g-definer-study-protocol-of-an-observational-prospective-multicenter-study
#6
JOURNAL ARTICLE
Rosalba Miceli, Hanna Eriksson, Giuseppe Lo Russo, Salvatore Alfieri, Maria Moksnes Bjaanæs, Filippo Pietrantonio, Loris De Cecco, Arsela Prelaj, Claudia Proto, Johan Franzén, Deirdre McDonnell, José Javier Berenguer Pina, Teresa Beninato, Laura Mazzeo, Patrizia Giannatempo, Elena Verzoni, John Crown, Åslaug Helland, Alexander Eustace
BACKGROUND: Immune checkpoint inhibitors (ICIs) have significantly improved outcomes in various cancers. ICI treatment is associated with the incidence of immune-related adverse events (irAEs) which can affect any organ. Data on irAEs occurrence in relation to sex- differentiation and their association with gender-specific factors are limited. AIMS: The primary objective of the G-DEFINER study is to compare the irAEs incidence in female and male patients who undergo ICI treatment...
April 21, 2024: Acta Oncologica
https://read.qxmd.com/read/38646274/long-term-survival-of-a-patient-with-anaplastic-thyroid-carcinoma-treated-with-hypofractionated-radiotherapy-a-case-report
#7
Mitsuki Tanaka, Yoshiomi Hatayama, Hideo Kawaguchi, Ichitaro Fujioka, Masahiro Aoki
Anaplastic thyroid carcinoma, a rare type of primary thyroid cancer, is one of the most aggressive neoplasms with a poor prognosis. Many cases are in the advanced stage at the time of the initial visit, and curative treatment is impossible. Because of the highly radioresistant nature of anaplastic thyroid carcinoma, this condition cannot be properly controlled with conventional radiotherapy. Herein, we report the case of a patient with anaplastic thyroid carcinoma who underwent hypofractionated radiotherapy, attained a complete response, and is still alive more than 10 years after treatment with no evidence of disease...
March 2024: Curēus
https://read.qxmd.com/read/38636083/number-of-healthy-teeth-can-predict-the-response-of-rectal-cancer-to-chemoradiotherapy-a-retrospective-study
#8
JOURNAL ARTICLE
Toshihiro Nakao, Mitsuo Shimada, Kozo Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuma Wada, Toshiaki Yoshimoto
BACKGROUND: It has been reported that the oral and gut microbiomes are associated with the prognosis in patients who undergo surgery, chemotherapy, and radiation for colorectal cancer. This study is the first to identify a correlation between the number of healthy teeth, which is an oral health indicator, and the efficacy of preoperative chemotherapy for rectal cancer. METHODS: This retrospective single-center study included 30 patients who underwent radical surgery after preoperative chemoradiotherapy (CRT) between December 2013 and June 2021...
April 18, 2024: American Surgeon
https://read.qxmd.com/read/38635287/early-multicentric-outcomes-of-the-on-label-and-ce-marked-combination-of-the-endurant-with-the-radiant-chimney-graft-for-the-chimney-endovascular-aortic-repair-enchevar-the-lamur-registry
#9
JOURNAL ARTICLE
Marco V Usai, Efthymios Beropoulis, Stefano Fazzini, Konstantinos Avranas, Yousef Khatatba, Apostolos Pitoulias, Gergana T Taneva, Martin J Austermann, Konstantinos P Donas
BACKGROUND: The aim of this study was to evaluate the early results of the CE-marked standardized device combination consisting of Endurant and the Radiant chimney graft (En-ChEVAR) for the treatment of juxtarenal aortic aneurysms. METHODS: We analyzed multicentric non-industry sponsored case series evaluating the EnChEVAR technique for patients treated between December 2022 and February 2024. Clinical, perioperative procedure-related and radiological data were collected...
April 18, 2024: Journal of Cardiovascular Surgery
https://read.qxmd.com/read/38631536/efficacy-and-toxicity-of-moderately-hypofractionated-radiotherapy-with-helical-tomotherapy-versus-conventional-radiotherapy-in-patients-with-unresectable-stage-iii-non-small-cell-lung-cancer-receiving-concurrent-chemotherapy-a-multicentre-randomized-phase-iii
#10
REVIEW
Qi Zhang, Shaonan Fan, Xiaohong Xu, Shisuo Du, Guangying Zhu, Chaoyang Jiang, Shi-An Xia, Qiwen Li, Qifeng Wang, Dong Qian, Ming Zhang, Han Xiao, Gang Chen, Zhaochong Zeng, Jian He
PURPOSE: The standard treatment schedule for unresectable stage III non-small-cell lung cancer (NSCLC) is chemotherapy with concurrent radiotherapy (60 Gy delivered in 30 fractions), although moderately hypofractionated radiotherapy (Hypo-RT) has also been considered as an alternative strategy. This study aimed to compare the efficacy and toxicity of moderately Hypo-RT with helical TomoTherapy versus conventionally fractionated radiotherapy (Con-RT) in patients with unresectable stage III NSCLC receiving concurrent chemotherapy...
April 15, 2024: International Journal of Radiation Oncology, Biology, Physics
https://read.qxmd.com/read/38630954/phase-ii-single-arm-trial-of-induction-and-concurrent-vismodegib-with-curative-intent-radiation-therapy-for-locally-advanced-unresectable-basal-cell-carcinoma
#11
JOURNAL ARTICLE
Christopher A Barker, Suzanne Dufault, Sarah T Arron, Alan L Ho, Alain P Algazi, Lara A Dunn, Audrey A Humphries, Carter Hultman, Ming Lian, P Daniel Knott, Sue S Yom
PURPOSE: Locally advanced, unresectable basal cell carcinoma (LA BCC) can be treated with radiation therapy (RT), but locoregional control (LRC) rates are unsatisfactory. Vismodegib is a hedgehog pathway inhibitor (HPI) active in BCC that may radiosensitize BCC. We evaluated the combination of vismodegib and RT for patients with LA BCC. METHODS: In this multicenter, single-arm, phase II study, patients with unresectable LA BCC received 12 weeks of induction vismodegib, followed by 7 weeks of concurrent vismodegib and RT...
April 17, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38628415/immune-checkpoint-monoclonal-antibody-related-adverse-effects-in-neuro-ophthalmology
#12
JOURNAL ARTICLE
May Ameri, Nagham Al-Zubidi, Andrew G Lee
Immunotherapy has renovated the field of oncology. Usually, cancer is treated by surgery, chemotherapy, and radiation. Immunotherapy is a promising treatment that harnesses the patient's own immune system to target cancer. Immune checkpoint inhibitors (ICIs) have proven to be a promising treatment avenue for managing cancer; however, their use had been associated with a unique spectrum of adverse side effects called immune-related adverse events (irAEs). As ICIs become increasingly relevant in cancer management, it is crucial to address these irAEs affecting various systems in the body, including the skin, liver, gastrointestinal tract, endocrine system, and the eye...
2024: Saudi Journal of Ophthalmology: Official Journal of the Saudi Ophthalmological Society
https://read.qxmd.com/read/38627015/spontaneous-ureteral-rupture-during-a-99m-tc-mercaptoacetyltriglycine-renal-scan
#13
JOURNAL ARTICLE
Roxana Apostol, Paul Rodrigue
After therapeutic pelvic radiation for malignancy such as prostate cancer, patients are at greater risk for spontaneous ureteral rupture. Bladder outlet obstruction and other more proximal causes of obstruction also exacerbate this vulnerability. Here we present a case of spontaneous ureteral rupture during a 99m Tc-mercaptoacetyltriglycine nuclear renal scan secondary to Foley catheter obstruction in a 73-y-old man with a prior ureteral reimplantation procedure. Prompt detection of Foley catheter malfunction could potentially prevent such adverse events...
April 16, 2024: Journal of Nuclear Medicine Technology
https://read.qxmd.com/read/38621607/safety-and-efficacy-of-stereotactic-body-radiotherapy-for-ultra-central-thoracic-tumours-a-single-centre-retrospective-review
#14
JOURNAL ARTICLE
George J Li, Hendrick Tan, Humza Nusrat, Joe Chang, Hanbo Chen, Ian Poon, Jeevin Shahi, May Tsao, Yee Ung, Patrick Cheung, Alexander V Louie
PURPOSE/OBJECTIVE(S): We sought to evaluate the toxicity and efficacy of stereotactic body radiotherapy (SBRT) for ultra-central thoracic tumours at our institution. MATERIALS/METHODS: Patients with ultra-central lung tumours or nodes, defined as having the planning target volume (PTV) overlapping or abutting the central bronchial tree and/or esophagus, treated at our institution with SBRT between 2009 and 2019 were retrospectively reviewed. All SBRT plans were generated with the goal of creating homogenous dose distributions...
April 13, 2024: International Journal of Radiation Oncology, Biology, Physics
https://read.qxmd.com/read/38619669/combined-dasatinib-and-quercetin-treatment-contributes-to-skin-rejuvenation-through-selective-elimination-of-senescent-cells-in-vitro-and-in-vivo
#15
JOURNAL ARTICLE
Kento Takaya, Kazuo Kishi
The skin's protective functions are compromised over time by both endogenous and exogenous aging. Senescence is well-documented in skin phenotypes, such as wrinkling and sagging, a consequence of the senescence-associated secretory phenotype (SASP) that involves the accumulation of senescent fibroblasts, chronic inflammation, and collagen remodeling. Although therapeutic approaches for eliminating senescent cells from the skin are available, their efficacy remains unclear. Accordingly, we aimed to examine the effects of dasatinib in combination with quercetin (D + Q) on senescent human skin fibroblasts and aging human skin...
April 15, 2024: Biogerontology
https://read.qxmd.com/read/38618919/clinical-manifestation-risk-factors-and-immune-checkpoint-inhibitor-rechallenge-of-checkpoint-inhibitor-associated-pneumonitis-in-patients-with-lung-cancer
#16
JOURNAL ARTICLE
Xuemeng Li, Fang Yang, Baogang Liu, Leiguang Ye, Jingwen Du, Xiaona Fan, Yue Yu, Mengwei Li, Li Bu, Zhuoqi Zhang, Lili Xie, Wuquan Li, Jiaqing Qi
Immune-related adverse effects can lead to damage to various systems of the body, checkpoint inhibitor-associated pneumonitis (CIP) is one of the potentially lethal immune-related adverse effects. However, evidence regarding the risk factors associated with CIP is limited. To timely and accurate identification and prompt treatment of CIP, understanding the risk factors for multimorbidity among diverse study populations becomes crucial. We retrospectively analyzed the clinical data of 1131 patients with lung cancer receiving immunotherapy to identify 110 patients with CIP, the clinical characteristics and radiographic features of patients with CIP were analyzed...
April 15, 2024: Journal of Immunotherapy
https://read.qxmd.com/read/38617757/clinical-radiomics-nomogram-for-the-risk-prediction-of-esophageal-fistula-in-patients-with-esophageal-squamous-cell-carcinoma-treated-with-intensity-modulated-radiation-therapy-or-volumetric-modulated-arc-therapy
#17
JOURNAL ARTICLE
Zhaohui Li, Jie Gong, Liu Shi, Jie Li, Zhi Yang, Guangjin Chai, Bo Lv, Geng Xiang, Bin Wang, Shamus R Carr, Alfonso Fiorelli, Mei Shi, Yilin Zhao, Lina Zhao
BACKGROUND: Esophageal fistula (EF) is a serious adverse event as a result of radiotherapy in patients with esophageal cancer (EC). We aimed to identify the predictive factors and establish a prediction model of EF in patients with esophageal squamous cell carcinoma (ESCC) who underwent intensity-modulated radiation therapy (IMRT) or volumetric-modulated arc therapy (VMAT). METHODS: Patients with ESCC treated with IMRT or VMAT from January 2013 to December 2020 at Xijing Hospital were retrospectively analyzed...
March 29, 2024: Journal of Thoracic Disease
https://read.qxmd.com/read/38615887/first-in-human-phase-i-clinical-trial-of-stereotactic-irradiation-to-achieve-lung-volume-reduction-silvr-in-severe-emphysema
#18
JOURNAL ARTICLE
Devanish N Kamtam, Michael S Binkley, Ntemena Kapula, Cheyenne Sadeghi, Shannon Nesbit, Haiwei Henry Guo Md, Joon Chang, Peter G Maxim, Maximilian Diehn, Billy W Loo, Joseph B Shrager
PURPOSE: Only a subset of patients with severe emphysema qualify for lung volume reduction surgery or endobronchial valves. We previously demonstrated that Stereotactic Ablative Radiotherapy (SABR) of lung tumors reduces lung volume in treated lobes by creating localized lung fibrosis. We aimed to determine the safety and, secondarily, explore the efficacy of Stereotactic Irradiation for Lung Volume Reduction (SILVR) over 18 months following intervention in patients with severe emphysema...
April 12, 2024: International Journal of Radiation Oncology, Biology, Physics
https://read.qxmd.com/read/38615197/multicenter-evaluation-of-the-safety-and-efficacy-of-selective-internal-radiation-therapy-with-yttrium-90-resin-microspheres-in-taiwan-data-from-the-resin-registry
#19
JOURNAL ARTICLE
Rheun-Chuan Lee, Po-Chin Liang, Huei-Lung Liang, Yung-Fang Chen, Chun-Yen Yu, Pin-Nan Cheng, Chien-Fu Hung, Cheng-Yuan Hsia, Hsueh-Chou Lai, Ming-Chih Ho, Yu-Fan Cheng, Yi-Sheng Liu, Yee Chao, Chien-Hung Chen
BACKGROUND AND AIM: The REgistry of Selective Internal radiation therapy in AsiaNs (RESIN) was a multicenter, single-arm, prospective, observational study of 90 Y resin microspheres in patients with hepatocellular carcinoma (HCC) or metastatic colorectal cancer (mCRC) from Taiwan. RESIN is the first real-life clinical study of this therapy in an Asian cohort. Study objectives were to evaluate the safety and efficacy of 90 Y resin microspheres. METHODS: Adults with HCC or mCRC scheduled to receive SIRT with 90 Y resin microspheres were included...
April 13, 2024: Journal of Gastroenterology and Hepatology
https://read.qxmd.com/read/38614284/long-term-survival-outcomes-and-quality-of-life-of-image-guided-proton-therapy-for-operable-stage-i-non-small-cell-lung-cancer-a-phase-2-study
#20
JOURNAL ARTICLE
Koichiro Nakajima, Masanosuke Oguri, Hiromitsu Iwata, Yukiko Hattori, Shingo Hashimoto, Kento Nomura, Kensuke Hayashi, Toshiyuki Toshito, Kenji Akita, Fumiya Baba, Hiroyuki Ogino, Akio Hiwatashi
BACKGROUND AND PURPOSE: This study evaluated long-term efficacy, safety, and changes in quality of life (QOL) of patients after image-guided proton therapy (IGPT) for operable stage I non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: This single-institutional prospective phase 2 study enrolled patients with operable histologically confirmed stage IA or IB NSCLC (7th edition of UICC). The prescribed dose was 66 Gy relative biological effectiveness equivalents (GyRBE) in 10 fractions for peripheral lesions, or 72...
April 11, 2024: Radiotherapy and Oncology
keyword
keyword
160170
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.